Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 435Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 2Dolutegravir Products

02 3Dolutegravir products

03 5Dovato

04 7Juluca

05 10Tivicay

06 5Triumeq

PharmaCompass

01

Brand Name : Triumeq

Dolutegravir

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Triumeq

arrow
2024 ACI Convention
Not Confirmed

Dolutegravir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 3,197

2019 Revenue in Millions : 3,534

Growth (%) : -10

blank

02

Brand Name : Dovato

Dolutegravir

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Dovato

arrow
2024 ACI Convention
Not Confirmed

Dolutegravir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 518

2019 Revenue in Millions : 78

Growth (%) : 568

blank

03

Brand Name : Tivicay

Dolutegravir

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tivicay

arrow
2024 ACI Convention
Not Confirmed

Dolutegravir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 2,117

2019 Revenue in Millions : 2,304

Growth (%) : -8

blank

04

Brand Name : Juluca

Dolutegravir

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Juluca

arrow
2024 ACI Convention
Not Confirmed

Dolutegravir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 686

2019 Revenue in Millions : 507

Growth (%) : 35

blank

05

Brand Name : Dolutegravir products

Dolutegravir

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Dolutegravir products

arrow
2024 ACI Convention
Not Confirmed

Dolutegravir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 6,519

2019 Revenue in Millions : 6,423

Growth (%) : 1

blank

06

Brand Name : Juluca

Dolutegravir

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Juluca

arrow
2024 ACI Convention
Not Confirmed

Dolutegravir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 700

2020 Revenue in Millions : 678

Growth (%) : 4

blank

07

Brand Name : Dolutegravir products

Dolutegravir

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Dolutegravir products

arrow
2024 ACI Convention
Not Confirmed

Dolutegravir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 6,181

2020 Revenue in Millions : 6,442

Growth (%) : -3

blank

08

Brand Name : Triumeq

Dolutegravir

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Triumeq

arrow
2024 ACI Convention
Not Confirmed

Dolutegravir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 2,547

2020 Revenue in Millions : 3,159

Growth (%) : -18

blank

09

Brand Name : Dovato

Dolutegravir

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Dovato

arrow
2024 ACI Convention
Not Confirmed

Dolutegravir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 1,065

2020 Revenue in Millions : 512

Growth (%) : 110

blank

10

Brand Name : Tivicay

Dolutegravir

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tivicay

arrow
2024 ACI Convention
Not Confirmed

Dolutegravir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 1,869

2020 Revenue in Millions : 2,092

Growth (%) : -10

blank